[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"megestrol-acetate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:megestrol-acetate":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100602984","phase-1-evaluation-of-the-efficacy-and-safety-of-megestrol-acetate-in-preventing-nausea-and-vomiting-induced-by-highly-emetogenic-chemotherapy-100602984",false,"NCT07130617","Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy","A Phase Ib, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Clinical Study Evaluating the Efficacy and Safety of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of sex\n2. Histologically or cytologically confirmed lung cancer\n3. Expected survival ≥ 3 months\n4. Female subjects of childbearing potential must have negative serum pregnancy test within 72 hours prior to randomization and must be non-lactating\n5. Capable of comprehending and willingly providing signed informed consent form (ICF), and adhering to study requirements\u002Frestrictions Exclusion Criteria\n\n1\\. Received or scheduled to receive concurrent radiotherapy within 7 days prior to enrollment through Day 1-8 of treatment 2. Systemic corticosteroid therapy or sedating antihistamines within 7 days prior to enrollment 3. Poorly controlled serous cavity effusions (pleural\u002Fperitoneal\u002Fpericardial) 4. Severe cardiovascular diseases within 3 months prior to enrollment 5. Participation in other clinical trials within 30 days prior to enrollment","ALL","18 Years",{"count":19,"type":20},132,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","To evaluate the efficacy of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy in Malignant Solid Tumor Patients",[26,27,28,29],"Efficacy","Safety","Megestrol Acetate","Adult Subject","NOT_YET_RECRUITING","2025-08-12",{"date":33,"type":34},"2025-08-19","ACTUAL",{"date":36,"type":20},"2025-09-29",{"date":38,"type":20},"2026-07-31",{"name":40,"class":41},"Changchun GeneScience Pharmaceutical Co., Ltd.","INDUSTRY"]